Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
61 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Burden and Treatment of Achondroplasia: A Systematic Literature Review.
Murton MC, Drane ELA, Goff-Leggett DM, et al. · Adv Ther · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial.
Savarirayan R, McDonnell C, Bacino CA, et al. · JAMA Pediatr · 2026Randomized Controlled Trial, Multicenter Study
- Achondroplasia: Really rhizomelic?
Shelmerdine SC, Brittain H, Arthurs OJ, et al. · Am J Med Genet A · 2016Meta-Analysis, Research Support, Non-U.S. Gov't
- Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence.
Albuquerque ALB, Dacoregio MI, Rodrigues CG, et al. · Genet Med · 2026Systematic Review, Meta-Analysis
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Savarirayan R, Tofts L, Irving M, et al. · Lancet · 2020Clinical Trial, Phase III, Multicenter Study
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Savarirayan R, Tofts L, Irving M, et al. · Genet Med · 2021Clinical Trial, Phase III, Randomized Controlled Trial
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
Savarirayan R, Wilcox WR, Harmatz P, et al. · Lancet Child Adolesc Health · 2024Clinical Trial, Phase II, Multicenter Study
- Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
Savarirayan R, Irving M, Wilcox WR, et al. · Med · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.
Savarirayan R, Hoover-Fong J, Irving M, et al. · N Engl J Med · 2026Randomized Controlled Trial, Multicenter Study
- Oral Infigratinib Therapy in Children with Achondroplasia.
Savarirayan R, De Bergua JM, Arundel P, et al. · N Engl J Med · 2025Multicenter Study, Clinical Trial, Phase II
- [Syringomyelia in children].
Zérah M · Neurochirurgie · 1999Clinical Trial, English Abstract
- Birth prevalence of achondroplasia: A systematic literature review and meta-analysis.
Foreman PK, van Kessel F, van Hoorn R, et al. · Am J Med Genet A · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life.
Savarirayan R, Irving M, Wilcox WR, et al. · Genet Med · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Growth hormone therapy in achondroplasia.
Seino Y, Yamanaka Y, Shinohara M, et al. · Horm Res · 2000Clinical Trial, Randomized Controlled Trial
- Growth hormone therapy in achondroplasia.
Nishi Y, Kajiyama M, Miyagawa S, et al. · Acta Endocrinol (Copenh) · 1993Clinical Trial
- Progress report: growth hormone in skeletal dysplasia.
Bridges NA, Brook CG · Horm Res · 1994Clinical Trial, Review
- Molecular and Genetic Mechanisms of Spinal Stenosis Formation: Systematic Review.
Byvaltsev VA, Kalinin AA, Hernandez PA, et al. · Int J Mol Sci · 2022Systematic Review
- Impact of achondroplasia on Latin American patients: a systematic review and meta-analysis of observational studies.
Fano V, Kim CA, Rosselli P, et al. · Orphanet J Rare Dis · 2022Meta-Analysis, Research Support, Non-U.S. Gov't
- A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.
Dauber A, Savarirayan R, Campeau PM, et al. · NEJM Evid · 2026Clinical Trial, Phase III, Randomized Controlled Trial
- Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders.
Faruqi T, Dhawan N, Bahl J, et al. · Biomed Res Int · 2014Systematic Review
- Efficacy and safety of Vosoritide in achondroplasia: A systematic review and meta-analysis.
Pahuja M, Prakash C, Umrao A, et al. · Indian J Med Res · 2026Systematic Review, Meta-Analysis
- C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
Savarirayan R, Irving M, Bacino CA, et al. · N Engl J Med · 2019Clinical Trial, Phase II, Multicenter Study
- Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
Chan ML, Qi Y, Larimore K, et al. · Clin Pharmacokinet · 2022Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy and safety of vosoritide in children with achondroplasia: a systematic review and meta-analysis.
Alfaraj GA, Alfaraj HA, Adel M, et al. · Eur J Pediatr · 2026Systematic Review, Meta-Analysis
- Efficacy and safety of limb lengthening in achondroplasia: A systematic review and meta-analysis.
Hosny G, AbdElnaser A, Elashhab A, et al. · Int Orthop · 2026Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.